A Bivalent Vaccine Based on a Replication-Incompetent Influenza Virus Protects against Streptococcus pneumoniae and Influenza Virus Infection

ABSTRACT Streptococcus pneumoniae is a major causative pathogen in community-acquired pneumonia; together with influenza virus, it represents an important public health burden. Although vaccination is the most effective prophylaxis against these infectious agents, no single vaccine simultaneously provides protective immunity against both S. pneumoniae and influenza virus. Previously, we demonstrated that several replication-incompetent influenza viruses efficiently elicit IgG in serum and IgA in the upper and lower respiratory tracts. Here, we generated a replication-incompetent hemagglutinin knockout (HA-KO) influenza virus possessing the sequence for the antigenic region of pneumococcal surface protein A (PspA). Although this virus (HA-KO/PspA virus) could replicate only in an HA-expressing cell line, it infected wild-type cells and expressed both viral proteins and PspA. PspA- and influenza virus-specific antibodies were detected in nasal wash and bronchoalveolar lavage fluids and in sera from mice intranasally inoculated with HA-KO/PspA virus, and mice inoculated with HA-KO/PspA virus were completely protected from lethal challenge with either S. pneumoniae or influenza virus. Further, bacterial colonization of the nasopharynx was prevented in mice immunized with HA-KO/PspA virus. These results indicate that HA-KO/PspA virus is a promising bivalent vaccine candidate that simultaneously confers protective immunity against both S. pneumoniae and influenza virus. We believe that this strategy offers a platform for the development of bivalent vaccines, based on replication-incompetent influenza virus, against pathogens that cause respiratory infectious diseases. IMPORTANCE Streptococcus pneumoniae and influenza viruses cause contagious diseases, but no single vaccine can simultaneously provide protective immunity against both pathogens. Here, we used reverse genetics to generate a replication-incompetent influenza virus carrying the sequence for the antigenic region of pneumococcal surface protein A and demonstrated that mice immunized with this virus were completely protected from lethal doses of infection with either influenza virus or Streptococcus pneumoniae. We believe that this strategy, which is based on a replication-incompetent influenza virus possessing the antigenic region of other respiratory pathogens, offers a platform for the development of bivalent vaccines.

[1]  Steven F. Baker,et al.  Protection against Lethal Influenza with a Viral Mimic , 2013, Journal of Virology.

[2]  H. Katsura,et al.  A replication-incompetent virus possessing an uncleavable hemagglutinin as an influenza vaccine. , 2012, Vaccine.

[3]  E. Fodor,et al.  Pseudotyped Influenza A Virus as a Vaccine for the Induction of Heterotypic Immunity , 2012, Journal of Virology.

[4]  K. Klugman,et al.  The future of pneumococcal disease prevention. , 2011, Vaccine.

[5]  R. Malley,et al.  Next generation pneumococcal vaccines. , 2011, Current opinion in immunology.

[6]  M. Chaussee,et al.  Inactivated and live, attenuated influenza vaccines protect mice against influenza: Streptococcus pyogenes super-infections. , 2011, Vaccine.

[7]  T. Randall,et al.  Contributions of Antinucleoprotein IgG to Heterosubtypic Immunity against Influenza Virus , 2011, The Journal of Immunology.

[8]  K. Ishii,et al.  Intranasal vaccination with pneumococcal surface protein A plus poly(I:C) protects against secondary pneumococcal pneumonia in mice. , 2011, Vaccine.

[9]  J. McCullers,et al.  Contribution of Vaccine-Induced Immunity toward either the HA or the NA Component of Influenza Viruses Limits Secondary Bacterial Complications , 2010, Journal of Virology.

[10]  R. Heyderman,et al.  Potential role for mucosally active vaccines against pneumococcal pneumonia , 2010, Trends in microbiology.

[11]  D. Mollura,et al.  Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. , 2010, Archives of pathology & laboratory medicine.

[12]  J. Kaldor,et al.  Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[13]  G. Palacios,et al.  Streptococcus pneumoniae Coinfection Is Correlated with the Severity of H1N1 Pandemic Influenza , 2009, PloS one.

[14]  N. Cox,et al.  Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. , 2009 .

[15]  K. Oishi,et al.  Intranasal immunization with a mixture of PspA and a Toll-like receptor agonist induces specific antibodies and enhances bacterial clearance in the airways of mice. , 2009, Vaccine.

[16]  C. Ambrose,et al.  Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza , 2008, Influenza and other respiratory viruses.

[17]  Anthony S Fauci,et al.  Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. , 2008, The Journal of infectious diseases.

[18]  T. Randall,et al.  A Novel Role for Non-Neutralizing Antibodies against Nucleoprotein in Facilitating Resistance to Influenza Virus1 , 2008, The Journal of Immunology.

[19]  Jeffrey N. Weiser,et al.  The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease , 2008, Nature Reviews Microbiology.

[20]  D. Briles,et al.  Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae. , 2008, Microbial pathogenesis.

[21]  E. Miyaji,et al.  Optimized Immune Response Elicited by a DNA Vaccine Expressing Pneumococcal Surface Protein A Is Characterized by a Balanced Immunoglobulin G1 (IgG1)/IgG2a Ratio and Proinflammatory Cytokine Production , 2008, Clinical and Vaccine Immunology.

[22]  A. Osterhaus,et al.  Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. , 2007, Current opinion in biotechnology.

[23]  M. J. Jedrzejas.  Unveiling molecular mechanisms of bacterial surface proteins: Streptococcus pneumoniae as a model organism for structural studies , 2007, Cellular and Molecular Life Sciences.

[24]  Gunther Hartmann,et al.  5'-Triphosphate RNA Is the Ligand for RIG-I , 2006, Science.

[25]  A. Pichlmair,et al.  RIG-I-Mediated Antiviral Responses to Single-Stranded RNA Bearing 5'-Phosphates , 2006, Science.

[26]  J. McCullers.  Insights into the Interaction between Influenza Virus and Pneumococcus , 2006, Clinical Microbiology Reviews.

[27]  R. Medzhitov,et al.  Toll-dependent selection of microbial antigens for presentation by dendritic cells , 2006, Nature.

[28]  D. Briles,et al.  Nasal Colonization with Streptococcus pneumoniae Includes Subpopulations of Surface and Invasive Pneumococci , 2005, Infection and Immunity.

[29]  R. Flavell,et al.  Toll-like receptor 3 promotes cross-priming to virus-infected cells , 2005, Nature.

[30]  Shizuo Akira,et al.  Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA , 2004, Science.

[31]  R. de Groot,et al.  Streptococcus pneumoniae colonisation: the key to pneumococcal disease. , 2004, The Lancet. Infectious diseases.

[32]  R. Cox,et al.  Influenza Virus: Immunity and Vaccination Strategies. Comparison of the Immune Response to Inactivated and Live, Attenuated Influenza Vaccines , 2004, Scandinavian journal of immunology.

[33]  D. Briles,et al.  Effects of PspA and Antibodies to PspA on Activation and Deposition of Complement on the Pneumococcal Surface , 2004, Infection and Immunity.

[34]  Steven Black,et al.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. , 2003, The Journal of pediatrics.

[35]  Yoshihiro Kawaoka,et al.  Exploitation of Nucleic Acid Packaging Signals To Generate a Novel Influenza Virus-Based Vector Stably Expressing Two Foreign Genes , 2003, Journal of Virology.

[36]  D. Briles,et al.  Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. , 2003, The Journal of infectious diseases.

[37]  R. Dagan,et al.  Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers , 2003, The Pediatric infectious disease journal.

[38]  A. Schuchat,et al.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. , 2003, The New England journal of medicine.

[39]  S. Dowell,et al.  Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis , 2000, Pediatrics.

[40]  D. Briles,et al.  Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. , 2000, Vaccine.

[41]  U. Bauer,et al.  [Centers for Disease Control and Prevention (CDC)]. , 2000, Annales de dermatologie et de venereologie.

[42]  Tokiko Watanabe,et al.  Generation of influenza A viruses entirely from cloned cDNAs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[43]  D. Greenberg,et al.  Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. , 1996, The Journal of infectious diseases.

[44]  K. Martin,et al.  Nuclear transport of influenza virus ribonucleoproteins: The viral matrix protein (M1) promotes export and inhibits import , 1991, Cell.

[45]  R. Webster,et al.  Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus. , 1982, Virology.